Announcements Trials
Browse Landscape

Phase

Phase 1 12Phase 2 5Phase 3 2Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Breast 1

Conditions

Ovarian Neoplasms 8Breast Neoplasms 8Prostatic Neoplasms 5Small Cell Lung Carcinoma 4Stomach Neoplasms 3Neoplasms 3Lung Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Recurrence 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Glioma 2Uterine Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Pheochromocytoma 1Peritoneal Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms by Site 1Metastatic Castration-Resistant Prostate Cancer 1Meningioma 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 21Paclitaxel 17Capecitabine 16fludarabine 14Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × olaparib × Clear all
NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

Lantern Pharma Inc.

Phase 1/2 Active not recruiting
64 enrolled
Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT05898399 2026-05-01

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Artios Pharma Ltd

Phase 1/2 Recruiting
181 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡